METHOD FOR TGFα
NeuroRepair has obviated the dangers and difficulties of intracranial infusion of TGFand the inability of intravenous TGF to cross the blood-brain barrier.
In animal studies conducted at the University of California, our scientists demonstrated the efficacy of intranasal administration of PEGylated TGFα. They developed NeuroRepair's patented process for intranasal delivery of PEGylated TGFα proteins to treat neurological damage.
One reason NeuroRepair has developed 143 mutants of TGFα is to discover one or more variants that are resistant to enzymatic breakdown without using PEGylation.
Matthew KlipsteinFounder and CEO
Mr. Klipstein is the CEO of NeuroRepair, Inc., a company whose patented technology has shown efficacy in treating neurological damage.
Matthew Klipstein is a successful entrepreneur who founded NeuroRepair in 2004, engaging scientists at the University of California to build on promising research in treating neurological damage caused by injury or disease. Their studies demonstrated a viable therapeutic strategy for both chronic stroke and Parkinson’s disease, and resulted in NeuroRepair's patented administration process. Mr. Klipstein has since sponsored the development of mutants of the protein used in the patented process.
Prior to founding NeuroRepair, Mr. Klipstein co-founded and served as CEO of Digital Stock Corporation. The company was an early disruptor and industry leader in the digital space, and the first to market digital storage and distribution of high-quality stock photography. Within five years of its establishment, Digital Stock was acquired by the Corbis Corporation.
Mr. Klipstein graduated with Honors from the University of California at Berkeley and from the University of Colorado School of Law. Following law school he served as a law clerk to a federal judge, and then was a founding partner in a San Francisco firm until retiring from the practice of law at age 34 to pursue business interests.
James Fallon, Ph.DChief Science Officer
Dr. Fallon is Professor Emeritus of Anatomy and Neurobiology at the University of California, Irvine.
Dr. Fallon is a Sloan and NIH RCDA Research Scholar and holds Doctoris Honoris and Research Excellence and Teaching Awards from multiple institutions. He is a Senior Research Fulbright Fellow. He has been elected President of the UC Irvine Faculty and Chair of the Medical School faculty and is the developer of numerous novel medical and research training models.
Dr. Fallon discovered a characterized growth factor in the mammalian brain (1984) and was first to demonstrate how to mobilize significant numbers of adult stem cells and progenitors in the injured brain (1997, 2000), a unique finding highlighted in the NIH Stem Cell report to Congress.
His lab localized EGF, TGF, and bFGF in the brain. He has written broadly on schizophrenia, addiction, and the basal ganglia, limbic system, and cortex. He was the neuroanatomist on the team that discovered the presence of extensive postnatal development of new neurons in the human brain, a discovery that was noted as one of the most startling and important findings during the decade of the brain.
Dr. Fallon carried out his doctoral training in Neuroanatomy and Neurophysiology at the University of Illinois and his postdoctoral training at the University of California, San Diego.
Jay M. Short, Ph.D
Dr. Short is Chairman, Chief Executive Officer, President and Cofounder of BioAtla® and a cofounder of Diversa Corporation (now BASF).
Diversa broke ground in developing enzymes, antibodies and biologically active compounds. Dr. Short is also the co-inventor of the BioAtla's patented Conditionally Active Biologics (CAB) platform.
Prior to joining Diversa, Dr. Short served as President of Stratacyte, an antibody engineering company and subsidiary of Stratagene (now Agilent). Stratacyte and Scripps Clinic were the first to clone and screen human antibody libraries in E. coli.
Dr. Short received a Bachelors degree in Chemistry with Honors from Taylor University. He received his Ph.D. in Biochemistry with additional studies in Macromolecular Science at Case Western Reserve University. Dr. Short is the author of more than 100 publications and is the inventor of over 500 pending patents (170 granted patents).
Dr. Short is the recipient of numerous awards, including Ernst & Young's Entrepreneur of the Year Award, the American Chemical Society's Henry F. Whalen, Jr. Award for Business Development, Adaptive Business Leaders' Innovations in HealthCare Gold Award, two of Connect's first place Most Innovative Product Awards, and in 2010 received an international Best-of-the-Best award from the Young Presidents Organization (YPO). He was shortlisted by the editorial board of Nature Biotechnology among those who made the most significant contribution to biotech in the past decade. Dr. Short joined the Neurorepair Science Advisory Board in March 2007.